Λίστα αντικειμένων
We discussed the results of a randomized study on Azacitidine with or
without eltrombopag for first-line treatment of intermediate- or
high-risk MDS with thrombocytopenia.
The study was closed premature because of a negative effect of
eltromombag both on thrombocytopenia and time to progress to AML.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris